Dirk Van Gestel

Dirk Van Gestel

Auto-generated profile, based on publicly available information

Dirk Van Gestel

Department of Radiotherapy, Institute Jules Bordet, Hopital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), 1070 Brussels, Belgium

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2019 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
Petr SzturzPetr Szturz
Petr Szturz
KWKristien Wouters
Kristien Wouters
NKNAOMI KIYOTA
NAOMI KIYOTA
MTMakoto Tahara
Makoto Tahara
KPKumar Prabhash
Kumar Prabhash
JVJan B. Vermorken
Jan B. Vermorken
In locally advanced squamous cell carcinomas of the head and neck (LA-SCCHN), concurrent chemoradiotherapy is an integral part of multimodality management both in the adjuvant and in the definitive settings. Although de-intensification strategies have been propelled to the forefront of clinical research in human papillomavirus (HPV) positive oropharyngeal cancer, three cycles of 100 mg/m2 cisplatin given every 3 weeks concurrently with conventionally fractionated external beam radiotherapy represent a cost-effective and globally accessible treatment option for the majority of LA-SCCHN cases. Based on four large randomized trials, this regimen has become the non-surgical standard of care for cisplatin-eligible patients. Nevertheless, the outcomes in terms of efficacy, toxicity, and compliance have been rather disappointing. Therefore, there is an unmet need to find a better alternative. With limited support from randomized trials, weekly low-dose cisplatin regimens have replaced the standard high-dose schedule at some institutions. Four prospective trials exploring radiotherapy with and without weekly low-dose cisplatin have been published. Two of them were conducted in the 1980s, one of which had a negative outcome, the third study provided insufficient information on toxicity, and the fourth trial had to be prematurely terminated due to poor accrual. Moreover, the findings of two phase III trials comparing the two concurrent cisplatin regimens favored the high-dose protocol. We performed a composite meta-analysis of 59 prospective trials enrolling a total of 5,582 patients. The primary endpoint was overall survival. Reflecting different radiotherapy fractionation schemes and treatment intents, three meta-analyses were carried out, one for postoperative conventional chemoradiotherapy, one for definitive conventional chemoradiotherapy, and one for definitive altered fractionation chemoradiotherapy. In the former two settings, both high- and low-dose regimens yielded similar survival outcomes, thus, the primary objective was not met. When given concurrently with altered fractionation radiotherapy, patients treated with high-dose cisplatin had significantly longer overall survival than those who received low-dose cisplatin. In this article we provide a synthetic view of the results, discuss the issue of cumulative dose, compare two vs. three cycles of high-dose cisplatin, and present our three-step recommendations for use of the current standard of care, high-dose cisplatin, in clinical practice.

12 October 2016 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
FHFien Hoefkens
Fien Hoefkens
CDCharlotte Dehandschutter
Charlotte Dehandschutter
JSJohan Somville
Johan Somville
PMPaul Meijnders
Paul Meijnders
DGDirk Van Gestel
Dirk Van Gestel
Soft tissue sarcomas are uncommon tumours of mesenchymal origin, most commonly arising in the extremities. Treatment includes surgical resection in combination with radiotherapy. Resection margins are of paramount importance in surgical treatment of soft tissue sarcomas but unambiguous guidelines for ideal margins of resection are still missing as is an uniform guideline on the use of radiotherapy. The present paper reviews the literature on soft tissue sarcomas of the extremities regarding the required resection margins, the impact of new radiotherapy techniques and the timing of radiotherapy, more particularly if it should be administered before or after surgical resection. This review was started by searching guidelines in different databases (National Guideline Clearinghouse, EBMPracticeNet, TRIP database, NCCN guidelines,…). After refinement of the query, more specific articles were found using MEDLINE, PubMed, Web of Science and Google Scholar. Used keywords include “soft tissue sarcoma”; “extremities OR limbs”; “radiotherapy”, “surgery”, “margins”, “local recurrence” and “overall survival”. Finally, the articles were selected based on the accessibility of the full text, use of the English language and relevance based on title and Literature demonstrates positive resection margins to be an important adverse prognostic factor for local recurrence of soft tissue sarcomas of the extremities. Still, no consensus is reached on the definition of what a good margin might be. The evolution of new radiation techniques, especially Intensity Modulated Radiotherapy, resulted in a s healthy surrounding tissues. However, the timing of radiotherapy treatment remains controversial as both preoperative and postoperative radiotherapy are characterised by several advantages and disadvantages.

1 May 2007 in The Oncologist
Verified
Journal Article
Closed access
PDF file
VGVincent Grégoire
Vincent Grégoire
WNWilfried De Neve
Wilfried De Neve
AEAvraham Eisbruch
Avraham Eisbruch
NLNancy Lee
Nancy Lee
DWDanielle Van Den Weyngaert
Danielle Van Den Weyngaert
DGDirk Van Gestel
Dirk Van Gestel
Learning Objectives: After completing this course, the reader will be able to: Outline innovations related to targeted radiation therapy.Describe trials proving an advantage using IMRT.Assess treatment planning modalities and how IMRT fields are designed.Evaluate when there is a toxicity advantage for IMRT.Discern when conventional radiotherapy should be used instead of IMRT. CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com

31 January 2013 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
AHAndrea Holt
Andrea Holt
DGDirk Van Gestel
Dirk Van Gestel
MAMark P Arends
Mark P Arends
Erik W. KorevaarErik W. Korevaar
Erik W. Korevaar
DSDanny Schuring
Danny Schuring
CVCorine van Vliet-Vroegindeweij
Corine van Vliet-Vroegindeweij
Background: Compared to static beam Intensity-Modulated Radiation Therapy (IMRT), the main advantage of Volumetric Modulated Arc Therapy (VMAT) is a shortened delivery time, which leads to improved patient comfort and possibly smaller intra-fraction movements. This study aims at a treatment planner-independent comparison of radiotherapy treatment planning of IMRT and VMAT for head-and-neck cancer performed by several institutes and based on the same CT- and contouring data. Methods: Five institutes generated IMRT and VMAT plans for five oropharyngeal cancer patients using either Pinnacle3 or Oncentra Masterplan to be delivered on Elekta linear accelerators. Results: Comparison of VMAT and IMRT plans within the same patient and institute showed significantly better sparing for almost all OARs with VMAT. The average mean dose to the parotid glands and oral cavity was reduced from 27.2 Gy and 39.4 Gy for IMRT to 25.0 Gy and 36.7 Gy for VMAT, respectively. The dose conformity at 95% of the prescribed dose for PTVboost and PTVtotal was 1.45 and 1.62 for IMRT and 1.37 and 1.50 for VMAT, respectively. The average effective delivery time was reduced from 13:15 min for IMRT to 5:54 min for VMAT. Conclusions: Independently of institution-specific optimization strategies, the quality of the VMAT plans including double arcs was superior to step-and-shoot IMRT plans including 5–9 beam ports, while the effective treatment delivery time was shortened by ~50% with VMAT.

1 March 2019 in Current Opinion in Oncology
Verified
Journal Article
Closed access
PBPauline De Bruyn
Pauline De Bruyn
DGDirk Van Gestel
Dirk Van Gestel
POPiet Ost
Piet Ost
VKVibeke Kruse
Vibeke Kruse
LBLieve Brochez
Lieve Brochez
SASandrine Aspeslagh
Sandrine Aspeslagh
Purpose of review: Checkpoint inhibitors (CPIs) provide impressive response rates among immunocompetent patients with various solid tumors. So far, organ transplant recipients have been excluded from clinical studies due to the putative risk of allograft rejection however 48 cases of liver and renal transplant patients treated with CPI were already described in literature. Recent findings: Here we discuss 19 cases of liver and 29 cases of renal transplant patients who received CPI for advanced cancer. Disease control rate [stable disease, complete response (CR) and partial response (PR) together] was 35% (21% for liver and 45% for kidney transplant patients). Graft rejection was seen in 37% of liver and 45% and kidney transplant patients. Significantly, our analysis shows that an ‘ideal’ response occurs in 21% of all patients (antitumor response accompanied with durable graft tolerance). Summary: We believe that transplant patients can be treated with CPI in a controlled setting and for well informed patients. To obtain a durable antitumor immune response while avoiding rejection, to be able to adjust immunosuppression and to have the opportunity to develop biomarkers for tumor response and transplant rejection, these patients should be treated according to a clinical care path or a prospective clinical trial.

1 November 2013 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
Sandra NuytsSandra Nuyts
Sandra Nuyts
MLMaarten Lambrecht
Maarten Lambrecht
FDFréderic Duprez
Fréderic Duprez
JDJean-Francois Daisne
Jean-Francois Daisne
DGDirk Van Gestel
Dirk Van Gestel
WNWilfried De Neve
Wilfried De Neve